News

Study Finds Potential Clinical Use of EGFR TKIs in BRAF Class 3–Mutated NSCLC

Can Deep Learning Models Predict Immunotherapy Response in Advanced NSCLC?

Researchers Look at Clinical Trial Eligibility Criteria for Those With Metastatic NSCLC

Surgery and Survival in Early-Stage Lung Cancer: Learning From Real-World Data

Combination of Chemotherapy, Immunotherapy, and Radiotherapy for NSCLC With Brain Metastases

EGFR-Mutant NSCLC: Weight Loss, Osimertinib, and Survival

Investigational Oral Therapy Receives Fast Track Designation for KRAS G12C–Mutated NSCLC

Study Plans to Evaluate Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

‘Knowing the Type of KRAS Mutation Is Critical’ in Managing KRAS-Mutant NSCLC

Use of Osimertinib and Cardiac Events: Is There a Connection?

Are Sodium Levels a Prognostic Indicator of Survival in Metastatic NSCLC?

Can Comprehensive Genome Profiling Determine the Right Treatment for Patients With NSCLC?

Can Selinexor Plus Docetaxel Improve Outcomes in Advanced KRAS-Mutant NSCLC?

FDA Approval: ALK Inhibitor Ensartinib for ALK-Positive Locally Advanced or Metastatic NSCLC

Adding Radiotherapy to TKIs in Metastatic EGFR-Mutated NSCLC Population

Combination of Sintilimab and Nab-Paclitaxel in Advanced Squamous NSCLC

Metformin: An Effective Treatment of Lung Cancer Among Patients With Obesity?

Algorithm for Capturing Disease Progression in Patients With Metastatic NSCLC

New Bispecific Antibody Granted Approval in NSCLC Harboring NRG1 Gene Fusion

Stage III NSCLC: Midtreatment PET-Adapted Radiotherapy Dose Escalation

California Researchers Awarded $2.5M Grant for Initiative to Reduce Disparities in Lung Cancer Screening

5-Year Outcomes From NADIM Trial Support Perioperative Chemoimmunotherapy in NSCLC

Creating Better Utility of Test Results in EGFR-Mutated Metastatic NSCLC

New Application for Accelerated Approval for Dato-DXd in Advanced EGFR-Mutated NSCLC

Chemoradiotherapy for Locally Advanced NSCLC: Is Dose Escalation the Answer to Local Tumor Control?

SITC 2024: Novel Method to Predict, Assess Immunotherapy Efficacy in NSCLC

SITC 2024: Updated Overall Survival From PERLA Trial in Metastatic Nonsquamous NSCLC

SITC 2024: Can Machine Learning Identify Treatment-Specific Outcomes and Biomarkers in NSCLC?

Wedge Resection or Lobectomy: Comparing Survival Benefits in NSCLC

SBRT vs Minimally Invasive Surgery in NSCLC: Clinical Model May Help in Selection Process

Relapse Patterns From Long-Term Subgroup Analysis of IMpower010

Using Machine Learning Model to Predict NSCLC Progression After Upfront Pembrolizumab

Combination Regimen vs Docetaxel in Advanced NSCLC

10-Year Update on Proton vs Photon Radiotherapy for Locally Advanced NSCLC

Perioperative Use of Ivonescimab in Resectable NSCLC

FDA Approves Tumor Treating Fields Therapy for Metastatic NSCLC

Exploring Comprehensive Biomarker Testing in Patients With NSCLC

Insights on Concomitant Driver Alterations in EGFR-Mutated NSCLC

ASTRO 2024: Combination of High-Dose Radiotherapy and Immunotherapy for Metastatic NSCLC

Novel Monoclonal Antibody Under Study in Phase III Trial of Nonsquamous NSCLC

ASTRO 2024: Can SBRT to the Primary Tumor Site Improve Outcomes in Metastatic NSCLC?

ESMO 2024: Targeting an Intestinal Bacterium to Improve Outcomes With Immunotherapy in NSCLC

ASTRO 2024: Role of Durvalumab With Radiotherapy for Some With Locally Advanced NSCLC

Neoadjuvant/Adjuvant Nivolumab With Chemotherapy Approved for Resectable NSCLC

Can Tusamitamab Ravtansine Improve Survival in CEACAM5-High NSCLC?

ASCO Quality 2024: Upfront Liquid Biopsy May Guide Therapeutic Options in NSCLC

ASCO Quality 2024: Can the Expansion of Medicaid Improve Clinical Outcomes in NSCLC?

ESMO 2024: Novel EGFR TKI After Amivantamab Therapy for Lung Cancer With EGFR Mutation

Osimertinib Approved for Treatment of Stage III NSCLC After Chemoradiotherapy

WCLC 2024: Adding JAK1 Inhibitor to Pembrolizumab in Metastatic PD-L1–Positive NSCLC

WCLC 2024: Novel Tyrosine Kinase Inhibitor vs Gefitinib in EGFR-Mutated NSCLC

Amivantamab Plus Chemotherapy Approved by FDA for NSCLC With Certain Genetic Mutations

WCLC 2024: Survival Update From TROPION-Lung01 on Dato-DXd vs Docetaxel in NSCLC

ESMO 2024: Update on Encorafenib Plus Binimetinib in BRAF V600E–Mutated NSCLC

ESMO 2024: Can Adding Corticosteroid to Radiotherapy for NSCLC Reduce Pneumonitis?

WCLC 2024: Ivonescimab vs Pembrolizumab in First-Line Treatment of PD-L1–Positive NSCLC

WCLC 2024: DUBLIN-3 Update on Plinabulin Plus Docetaxel in NSCLC

Molecular Mutations in NSCLC With Brain Metastases: Impact on Survival

WCLC 2024: Immunotherapy Before and After Surgery for NSCLC

WCLC 2024: AEGEAN Trial Update on Perioperative Durvalumab in Resectable NSCLC

LIBRETTO-431: East Asian Subgroup Analysis of Selpercatinib in RET-Positive NSCLC

Novel Triplet Under Study for Metastatic NSCLC: Early Phase II Results

Advanced NSCLC With MET Exon 14 Skipping Mutation: Focus on Novel MET Inhibitor

End-of-Life Care in Lung Cancer: Systemic Therapy Variability Among Oncologists

Atezolizumab Before and After Chemoradiation: Novel Plan for Unresectable Stage III NSCLC

NSCLC in Patients Older Than Age 75: Risks and Benefits of Surgery

Lung Cancer Screening in Low-Risk Individuals: More Harm Than Good?

Chemotherapy-Free Combination Approved by FDA for EGFR-Mutated NSCLC

How Intratumoral Bacteria Might Improve Outcomes With Immunotherapy for NSCLC

FDA Approves Use of Durvalumab With Chemotherapy Before and After Surgery in NSCLC

Is Immune Checkpoint Inhibition of Benefit in BRAF-Positive NSCLC?

Researchers Explore the Impact of Geographic Accessibility on Lung Cancer Screening